Skip to main content
SpringerLink
Log in

Entzündliche, endokrine und toxische Muskelerkrankungen

  • Chapter
Klinische Neurologie

  • 13k Accesses

Zusammenfassung

Die entzündlichen Muskelerkrankungen kommen im Rahmen von Systemerkrankungen oder in Assoziation mit Kollagenosen sowie erregerbedingt vor. Eine besondere Gruppe dieser Krankheiten sind idiopathische Myositiden – heterogene, sporadisch auftretende, erworbene und potenziell behandelbare entzündliche Erkrankungen der Skelettmuskulatur unklarer Ätiologie, die klinisch mit Muskelschwäche, Muskelatrophien, gelegentlich auch Muskelschmerzen und myohistologisch mit entzündlichen Infiltraten in der Muskulatur einhergehen. Die wichtigsten klinischen Krankheitsformen der idiopathischen Myositiden sind die Polymyositis (akuter Beginn), die Dermatomyositis (subakuter Beginn) und die Einschlusskörpermyositis (schleichender Beginn).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Zitierte Literatur

  • Argov Z, Tiram E, Eisenberg I et al. (1997) Various types of hereditary inclusion body myopathies map to chromosome 9p1–q1. Ann Neurol 41: 548–551

    Article  PubMed  CAS  Google Scholar 

  • Beyenburg S, Zierz S, Jerusalem F (1994) Einschlusskörpermyositis. Akt Neurol 21: 77–83

    Article  Google Scholar 

  • Bohan A, Peter JB, Bowman RL, Pearson CM (1977) A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 56: 255–286

    CAS  Google Scholar 

  • Brouwer R, Hengstman GJD, Vree Egberts W et al. (2001) Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60: 116–123

    Article  PubMed  CAS  Google Scholar 

  • Dahlbom K, Lindberg C, Oldfors A (2002) Inclusion body myositis: Morphological clues to correct diagnosis. Neuromuscul Disord 12: 853–857

    Article  PubMed  CAS  Google Scholar 

  • Dalakas MC (1992a) Clinical, immunopathologic, and therapeutic considerations of inflammatory myopathies. Clin Neuropharmacol 15: 327–351

    Article  CAS  Google Scholar 

  • Dalakas MC (1992b) Inflammatory and toxic myopathies. Curr Opin Neurol 5: 645–654

    CAS  Google Scholar 

  • Dalakas MC (1992c) Inflammatory myopathies: pathogenesis and treatment. Neuropharmacology 5: 327–351

    Google Scholar 

  • Dalakas MC (1992 d) Inflammatory myopathies. In: Rowland LP, Di-Mauro S (eds) Myopathies (Handbook of clinical neurology, vol 18). Elsevier, Amsterdam, pp 369–390

    Google Scholar 

  • Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362: 971–982

    Article  PubMed  CAS  Google Scholar 

  • Dalakas MC, Illa I, Dambrosia JM et al. (1993) A controlled trial of high-dose intravenous immune globuline infusions as treatment for dermatomyositis. N Engl J Med 329: 1993–2000

    Article  PubMed  CAS  Google Scholar 

  • Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion-body myositis with IVIG: A double-blind, placebo-controlled study. Neurology 48: 712–716

    PubMed  CAS  Google Scholar 

  • Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56: 323–327

    PubMed  CAS  Google Scholar 

  • De Vere R, Bradley WG (1975) Polymyositis: Its presentation, morbidity and mortality. Brain 98: 637–666

    Article  Google Scholar 

  • Eisenberg I, Hochner H, Shemesh M et al. (2001) Physical and transcriptional map of the hereditary inclusion body myopathy locus on chromosome 9p12–p13. Eur J Hum Genet 9: 501–509

    Article  PubMed  CAS  Google Scholar 

  • Genth E, Mierau R (1995) Diagnostic significance of scleroderma and myositis-associated autoantibodies. Z Rheumatol 54: 39–49

    PubMed  CAS  Google Scholar 

  • Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP (1995) Inclusion body myositis and myopathies. Ann Neurol 38: 705–713

    Article  PubMed  CAS  Google Scholar 

  • Hengstman GJD, Engelen BGM van, Venrooij WJ van (2004) Myositis specific autoantibodies: Changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 16: 69–699

    Google Scholar 

  • Hill CL, Zhang Y, Sigurgeirsson B et al. (2001) Lancet 357: 96–100

    Article  PubMed  CAS  Google Scholar 

  • Kayashima T, Matsuo H, Satoh A et al. (2002) Nonaka myopathy is caused by mutations in the UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase gene (GNE). J Hum Genet 47: 77–79

    Article  PubMed  CAS  Google Scholar 

  • Klein RQ, Teal V, Taylor L, Troxel AB, Werth VP (2007) Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J Am Acad Dermatol 57: 937–943

    Article  PubMed  Google Scholar 

  • Link E, Parish S, Armitage J et al. (2008) SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 359: 789–799

    Article  PubMed  CAS  Google Scholar 

  • Martinsson T, Darin N, Kyllermann M et al. (1999) Dominant hereditary inclusion body myopathy gene (IBM3) maps to chromosome region 17p13.1. Am J Hum Genet 64: 1420–1426

    Article  PubMed  CAS  Google Scholar 

  • Martinsson T, Oldfords A, Darin N et al. (2000) Autosomal dominant myopathy: missense mutation (Glu-706 →Lys) in the myosin heavy chain Iia gene. Proc Natl Acad Sci USA 97: 14614–14619

    Article  PubMed  CAS  Google Scholar 

  • Meulen MF van der, Bronner IM Hoogendijk JE et al. (2003) Polymyositis: an overdiagnosed entity. Neurology 61: 316–321

    PubMed  Google Scholar 

  • Moosmann B, Behl C (2004) Selenoprotein synthesis and side-effects of statins. Lancet 363: 892–894

    Article  PubMed  CAS  Google Scholar 

  • Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia FL (2008) Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 15: 1350–1353

    Article  PubMed  Google Scholar 

  • Pearson CM, Currie S (1974) Polymyositis and related disorders. In: Walton JN (ed) Disorders of voluntary muscle, 3rd edn. Churchill Livingstone, Edinburgh

    Google Scholar 

  • Schoser BG (2007) Ocular myositis: diagnostic assessment, differential diagnoses, and therapy of a rare muscle disease – five new cases and review. Clin Ophthalmol 1:37–42

    PubMed  Google Scholar 

  • Sivakumar K, Dalakas MC (1997) Inclusion body myositis and myopathies Curr Opin Neurol 10: 413–420

    Article  PubMed  CAS  Google Scholar 

  • Vasconcelos OM, Raju R, Dalakas MC (2002) GNE mutations in an American family with quadriceps-sparing IBM and lack of mutations in s-IBM. Neurology 59: 1776–1779

    PubMed  CAS  Google Scholar 

  • Walter MC, Lochmüller H, Toepfer M et al. (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebocontrolled study. J Neurol 247: 22–28

    Article  PubMed  CAS  Google Scholar 

  • Zierz S, Jerusalem F (2003) Muskelerkrankungen. Thieme, Stuttgart New York

    Google Scholar 

Weiterführende Literatur

  • Engel AG, Franzini-Armstrong C (1994) Myology. McGraw-Hill, New York

    Google Scholar 

  • Kissel JT, Mendell JR (1992) The endocrine myopathies. In: Rowland LP, Di-Mauro S (eds) Myopathies (Handbook of clinical neurology, vol 18). Elsevier, Amsterdam

    Google Scholar 

  • Mastaglia FL (1992) Toxic myopathies. In: Rowland LP, DiMauro S (eds) Myopathies (Handbook of clinical neurology, vol 18). Elsevier, Amsterdam

    Google Scholar 

  • Pongratz DE, Reimers CD, Hahn D, Nägele M, Müller-Felber W (1990) Atlas der Muskelkrankheiten. Urban & Schwarzenberg, München

    Google Scholar 

  • Walton J, Karpati G, Hilton-Jones D (1994) Disorders of voluntary muscle. Churchill Livingstone, Edinburgh

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ambulanz für Bewegungsstörungen, Klinik für Neurologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover

    P. Tacik

  2. Klinik und Poliklinik für Neurologie, Universitätsklinikum Halle (Saale), Ernst-Grube-Str. 40, 06097, Halle (Saale)

    Prof. Dr. S. Zierz

Authors
  1. P. Tacik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. S. Zierz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Neurologie, Alfried Krupp Krankenhaus Rüttenscheid, Alfried-Krupp-Straße 21, 45117, Essen

    Peter Berlit

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Tacik, P., Zierz, S. (2011). Entzündliche, endokrine und toxische Muskelerkrankungen. In: Berlit, P. (eds) Klinische Neurologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16920-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-16920-5_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-16919-9

  • Online ISBN: 978-3-642-16920-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation